CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells.
about
Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice.Targeting CD137 enhances the efficacy of cetuximab.CD137 expression is induced by Epstein-Barr virus infection through LMP1 in T or NK cells and mediates survival promoting signals.CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses.Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic miceImmunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospectsEmerging therapeutic targets in metastatic progression: A focus on breast cancer.CD137 expressed on neutrophils plays dual roles in antibacterial responses against Gram-positive and Gram-negative bacterial infections.Advances in targeting cell surface signalling molecules for immune modulationEmerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.Metastatic melanoma - a review of current and future drugsIntervention with costimulatory pathways as a therapeutic approach for graft-versus-host disease.Immunomodulating antibodies and drugs for the treatment of hematological malignancies.T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.A mathematical model of immune-system-melanoma competitionDelivering safer immunotherapies for cancer.Tumour necrosis factor receptor superfamily member 9 (TNFRSF9) is up-regulated in reactive astrocytes in human gliomas.Enhanced antitumor activity mediated by human 4-1BB-engineered T cells.Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity.A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
P2860
Q33603041-C6E43A76-2385-4AC3-8C40-F069DCE09A8EQ33872482-4A24C46E-A44B-4FBE-B9EE-9F5A387A9ECAQ34542208-446FF891-0C63-4042-8AA0-704CDD0B1E79Q34707604-1FF8DBE9-65AF-4856-BF15-200548A2F0C5Q35095630-7F46C63B-8592-437A-9F04-C809F9C68B2DQ35780315-F096D4C2-74F0-473F-B627-EE03FA5DAC4AQ36449290-ABD15041-4F21-4167-9DED-66F6060E52EDQ36697649-03AF22B4-B18D-48F6-BE5C-53C9CFCCF14DQ36778827-FB398A74-DB34-4D5B-8851-CF5E1614F709Q36854062-9D6DC22F-2B48-4827-B6A3-F0C7D8C2E0A3Q36911435-6D8038D3-06FA-48D8-B16E-33BC784F467AQ36973787-0E30C419-325F-4A1C-9D69-4DA8A66882F9Q37158481-1284FDAC-0F22-4DDD-84E9-726CFFD2713CQ37450733-B5D35329-9E97-4BA3-8C13-A5153A21F689Q37785736-CC09E4CE-B973-4253-97A5-3F3865752E94Q37832694-DED5D964-90EC-4469-866B-26A34B30D745Q37948129-E0294CE3-B5A0-44BE-8E2B-D9304E1AE847Q39330809-BA0BBCD4-7755-447E-87F3-5DBFB13265AFQ39330984-0915464B-B66A-4962-B91A-4514842A24BCQ44610668-CD327641-8D8F-4504-AD8A-B96980B1B3BFQ45441936-F7184221-BB7D-4554-A3D8-111A76B9F67CQ51738252-7DB5A137-2E67-496B-8B3D-2D09590FC77DQ52597566-C970BE9A-0D9C-4970-AE8E-30F093E6BFB5Q59136671-282FE833-837A-4A14-92E1-4B1149BE69A7
P2860
CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
CD137 agonist antibody prevent ...... ic and nonhematopoietic cells.
@ast
CD137 agonist antibody prevent ...... ic and nonhematopoietic cells.
@en
type
label
CD137 agonist antibody prevent ...... ic and nonhematopoietic cells.
@ast
CD137 agonist antibody prevent ...... ic and nonhematopoietic cells.
@en
prefLabel
CD137 agonist antibody prevent ...... ic and nonhematopoietic cells.
@ast
CD137 agonist antibody prevent ...... ic and nonhematopoietic cells.
@en
P2093
P2860
P1433
P1476
CD137 agonist antibody prevent ...... ic and nonhematopoietic cells.
@en
P2093
Gefeng Zhu
Hidehiko Narazaki
Lieping Chen
P2860
P304
P356
10.1182/BLOOD-2008-12-192591
P407
P577
2010-01-12T00:00:00Z